Moore Ryan A, Witten James C, Lowry Ashley M, Shrestha Nabin K, Blackstone Eugene H, Unai Shinya, Pettersson Gösta B, Wierup Per
Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
J Thorac Cardiovasc Surg. 2024 Jan;167(1):127-140.e15. doi: 10.1016/j.jtcvs.2022.01.058. Epub 2022 Apr 5.
The objectives of this study were to investigate patient characteristics, valve pathology, bacteriology, and surgical techniques related to outcome of patients who underwent surgery for isolated native (NVE) or prosthetic (PVE) mitral valve endocarditis.
From January 2002 to January 2020, 447 isolated mitral endocarditis operations were performed, 326 for NVE and 121 for PVE. Multivariable analysis of time-related outcomes used random forest machine learning.
Staphylococcus aureus was the most common causative organism. Of 326 patients with NVE, 88 (27%) underwent standard mitral valve repair, 43 (13%) extended repair, and 195 (60%) valve replacement. Compared with NVE with standard repair, patients who underwent all other operations were older, had more comorbidities, worse cardiac function, and more invasive disease. Hospital mortality was 3.8% (n = 17); 0 (0%) after standard valve repair, 3 (7.0%) after extended repair, 8 (4.1%) after NVE replacement, and 6 (5.0%) after PVE re-replacement. Survival at 1, 5, and 10 years was 91%, 75%, and 62% after any repair and 86%, 62%, and 44% after replacement, respectively. The most important risk factor for mortality was renal failure. Risk-adjusted outcomes, including survival, were similar in all groups. Unadjusted extended repair outcomes, particularly early, were similar or worse than replacement in terms of reinfection, reintervention, regurgitation, gradient, and survival.
A patient- and pathology-tailored approach to surgery for isolated mitral valve endocarditis has low mortality and excellent results. Apparent superiority of standard valve repair is related to patient characteristics and pathology. Renal failure is the most powerful risk factor. In case of extensive destruction, extended repair shows no benefit over replacement.
本研究旨在调查接受孤立性原发性(NVE)或人工瓣膜(PVE)二尖瓣心内膜炎手术患者的特征、瓣膜病理、细菌学及与手术结果相关的手术技术。
2002年1月至2020年1月,共进行了447例孤立性二尖瓣心内膜炎手术,其中326例为NVE,121例为PVE。对与时间相关的结果进行多变量分析时采用随机森林机器学习。
金黄色葡萄球菌是最常见的致病菌。在326例NVE患者中,88例(27%)接受了标准二尖瓣修复,43例(13%)接受了扩大修复,195例(60%)接受了瓣膜置换。与接受标准修复的NVE患者相比,接受其他所有手术的患者年龄更大,合并症更多,心功能更差,疾病侵袭性更强。医院死亡率为3.8%(n = 17);标准瓣膜修复后为0(0%),扩大修复后为3例(7.0%),NVE置换后为8例(4.1%),PVE再次置换后为6例(5.0%)。任何修复术后1年、5年和10年的生存率分别为91%、75%和62%,置换术后分别为86%、62%和44%。死亡的最重要危险因素是肾衰竭。包括生存率在内的风险调整后结果在所有组中相似。未调整的扩大修复结果,尤其是早期结果,在再感染、再次干预、反流、压差和生存率方面与置换相似或更差。
针对孤立性二尖瓣心内膜炎的患者和病理量身定制的手术方法死亡率低且效果良好。标准瓣膜修复的明显优势与患者特征和病理有关。肾衰竭是最有力的危险因素。在广泛破坏的情况下,扩大修复并不比置换更具优势。